The US FTC challenges the merger between a pharmaceutical company and a cancer detection test manufacturer (Grail / Illumina)

FTC Challenges Illumina’s Proposed Acquisition of Cancer Detection Test Maker Grail* Agency alleges vertical merger would harm competition in the U.S. market for life-saving Multi-Cancer Early Detection tests The Federal Trade Commission has filed an administrative complaint (a public version of which will be available and linked to this news release as soon as possible) and authorized a federal court lawsuit to block Illumina’s $7.1 billion proposed

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

Citation

US Federal Trade Commission, The US FTC challenges the merger between a pharmaceutical company and a cancer detection test manufacturer (Grail / Illumina), 30 mars 2021, e-Competitions March 2021, Art. N° 99896

Visites 466

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues